3818results about "Capsule delivery" patented technology

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The present invention discloses automated soft capsule production equipment and a speed regulation method, relating to the field of food and pharmaceutical equipment manufacturing, and is designed to achieve automated soft capsule production. The automated soft capsule production equipment includes an electronic control system, a liquid infusion system, a gelatin strip conveyor system, and a soft capsule pressing and molding system. The electronic control system is connected to the liquid infusion system, the gelatin strip conveyor system, and the soft capsule pressing and molding system, respectively. The gelatin strip conveyor system includes a thickness sensor for measuring the thickness of the conveyed gelatin strip and transmitting a measurement signal to the electronic control system. The gelatin strip conveyor system also includes an angle sensor assembly for measuring the tightness of the conveyed gelatin strip and transmitting a measurement signal to the electronic control system. The electronic control system receives and processes the measurement signal and transmits a control signal to a motor in the gelatin strip conveyor system to adjust the thickness or tightness of the gelatin strip. The liquid infusion system automatically closes and opens the infusion switch via the electronic control system, and the soft capsule pressing and molding system automatically controls the mold compression or release via the electronic control system.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The present invention relates to the use of N-palmitoylethanolamide (known as palmitoylethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug in the treatment of inflammatory pain. In particular, the present invention is directed to palmitoylethanolamide for use in the treatment of inflammatory pain, in particular non-neuropathic inflammatory pain, where palmitoylethanolamide is administered as needed in association or combination with a non-steroidal anti-inflammatory drug, where said administration is separate, combined, or simultaneous.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The invention belongs to the technical field of medical products, and provides a hydrogel dressing for diabetic chronic wounds and a preparation method and application of the hydrogel dressing. The antibacterial effect of the hydrogel dressing for the chronic wound surface of diabetes mellitus is improved by increasing the ZIF-8 coated AgNPs; in the hydrogel matrix part, the pH response is dominated by adjusting the component proportion of the temperature-sensitive agent N-isopropylacrylamide and the pH response 1-vinyl imidazole; the N-isopropylacrylamide assists the extension of a macromolecular chain segment in the composite hydrogel dressing, so that the dressing can fully absorb wound exudate and is easy to peel off, and secondary damage can be avoided.

Theranostic targeted ultrasonic blasting nano-bubbles, a preparation method therefor, and use thereof, wherein the nano-bubbles are the targeted drug-gene nano-bubbles miRNA / FTY720 / PFP@PEI-T7 NBs. The nano-bubbles can be used for preparing a thyroid ultrasound diagnostic agent or a drug for treating thyroid cancer.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention discloses an oral joint protection composition containing ergothioneine and a preparation method thereof, and relates to the technical field of joint protection compositions. The oral joint protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.05 to 5 parts of the ergothioneine, 20 to 50 parts of glucosamine salt, 10 to 30 parts of chondroitin sulfate, 2 to 10 parts of curcumin, 30 to 70 parts of a diluent, 1 to 10 parts of an adhesive, 0.5 to 5 parts of a lubricant, 2 to 10 parts of a disintegrating agent and 0.1 to 0.5 part of an antioxidant stabilizer. Through synergistic compatibility of active ingredients such as ergothioneine, curcumin and the like, a multi-dimensional action network of oxidation resistance, inflammation resistance and cartilage metabolism regulation is formed, the inhibition effect on joint inflammation is remarkably improved, and the limitation of a single ingredient is broken through.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The invention discloses a capsule medicament for endoscopic treatment of ulcerative colitis and a preparation method thereof, and belongs to the technical field of biological medicine, the capsule medicament is composed of a capsule matrix and a drug matrix; by adopting a dual control mechanism of an enteric layer coating and a pH response layer coating, accurate release of a medicine at a colon diseased region is ensured, medicine waste of the stomach and the small intestine is reduced, the medicine concentration at a focus is improved, mesalazine or budesonide is combined with the composite composition for treatment, inflammatory response is rapidly inhibited, acute symptoms are controlled, and the curative effect is good. A multi-mechanism synergistic treatment mode is adopted, the anti-inflammatory and repairing effects are enhanced, the clinical remission rate and the mucous membrane healing rate are remarkably improved, the pH response layer is dissolved in a colon alkaline environment, and the MMP-9 peptide cross-linking agent is subjected to enzymolysis at an inflammation part, so that the medicine is continuously released at a focus, the administration frequency is reduced, the compliance of a patient is improved, and the curative effect is good. In addition, the spherical gel particles in the medicament can prevent the medicament from being disintegrated too early in the intestinal tract, and the long-acting effect can be maintained.

The invention belongs to the technical field of medicines, and particularly relates to a composition for improving obesity and promoting cardiovascular health as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 5 to 20 parts of glycine betaine, 1 to 5.5 parts of choline chloride, 0.5 to 4 parts of L-theanine, 1 to 15 parts of alpha-ketoglutarate calcium, 0.5 to 3 parts of black ginger extract, 0.05 to 0.25 part of black pepper extract, 0.5 to 3 parts of ginkgo leaf extract and 1 to 6 parts of black garlic juice powder. According to the invention, the eight components are selected and are scientifically combined in an optimal quantity ratio range, and the prepared composition can better reduce the inflammation level of a body, regulate abnormal blood fat, improve the lipid metabolism disorder state and effectively reduce impulsive diet behaviors, so that comprehensive improvement of obesity and cardiovascular related risks is realized, and the health-care effect of a human body is improved. The body is effectively assisted to maintain metabolic health.

Embodiments include a method of diagnosing gastroparesis or suspected gastroparesis, the method comprising: obtaining data representing a time series of readings from gas sensing apparatus housed within a ingestible capsule device orally ingested by a subjected; processing the readings to detect one or more gastroparesis indicator spikes in the CO2 concentration with respect to time; based on the detected one or more gastroparesis indicator spikes in the CO2 concentration with respect to time, diagnosing gastroparesis or suspected gastroparesis.

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of tracking and locating the same are provided.

The present invention aims to provide a composition having excellent anti-aging properties. [Solution] A composition characterized by containing nicotinamide mononucleotide and at least one selected from the group consisting of pine bark, banaba, and fulvic acid.

Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

The invention belongs to the technical field of biological medicines, and particularly discloses a bionic nano-vesicle for regulating and controlling neutrophil phenotype in combination with ultrasound, and a preparation method and application of the bionic nano-vesicle. The bionic nano-vesicle provided by the invention can be broken under the action of high-concentration glutathione existing in a tumor tissue microenvironment to release the sound-sensitive agent and functional siRNA, and under the action of US irradiation, the sound-sensitive agent is activated to generate a large amount of ROS, promote tumor cell DNA breakage, generate a large amount of double-stranded DNA, activate APC and promote IFN-beta release, so that the tumor tissue microenvironment is inhibited. The released functional siRNA can promote the N2-type neutrophile granulocyte to become N1-type neutrophile granulocyte, and the released functional siRNA can prevent the N1-type neutrophile granulocyte from being reversed to the N2-type neutrophile granulocyte again, so that the regulation and control on the phenotype of the neutrophile granulocyte are realized; under catalysis of CAT rich in the thylakoid membrane, H2O2 overexpressed by tumor tissue is decomposed into oxygen, the tumor hypoxia microenvironment can be relieved, and the tumor treatment effect can be improved.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The invention discloses an automatic mold alignment device and method for a rolling model type soft capsule pelleting machine and the soft capsule pelleting machine, relates to the field of manufacturing of food and medicine equipment, and aims to realize automation of a soft capsule production link. According to the automatic mold alignment scheme of the rolling model soft capsule pelleting machine based on sensor detection, the sensor is used for detecting and recognizing the zero position phase difference of the two mold rollers, the position information is transmitted to the control system, and the control system automatically adjusts the relative positions of the two mold rollers, so that the automatic alignment of the two mold rollers is achieved. Therefore, the purpose of automatic alignment of the mold is achieved. According to the invention, the defects of the traditional manual alignment technology are overcome, and the quality and efficiency of soft capsule production are improved. Various sensor scheme selections are provided, including the laser displacement sensor, the contact type displacement sensor and the industrial camera, the appropriate scheme can be selected according to the actual demand, and remarkable economic benefits and social benefits are achieved.

Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4 / 5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

The invention provides a capsule and a preparation method thereof, the capsule comprises a core material and a rubber sheet wrapping the core material, the core material comprises an aqueous liquid preparation, an oily preparation and a structuring agent; the structuring agent comprises cellulose and / or a cellulose derivative, a low-molecular-weight lipid and a surfactant; the core material is paste, colloid or a solid-liquid mixture, and the core material can realize that the aqueous liquid preparation is stably dispersed and fixed in the oily preparation, so that the core material is stably wrapped by the rubber skin. The invention also discloses an aerosol generating product using the capsule.